Who is sponsoring NCT03112369?

NCT03112369 is sponsored by University of Washington.

What drugs are being tested in NCT03112369?

Interventions in NCT03112369: Narrative Exposure Therapy (NET), Motivational Interviewing w/Skills Training (MIST).

What condition does NCT03112369 study?

NCT03112369 studies HIV Prevention, PTSD and Substance Use Disorder.

Is NCT03112369 still recruiting?

NCT03112369 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT03112369

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use

Completed NA Last updated 19 September 2024

What this trial tests

NA trial testing Narrative Exposure Therapy (NET) in HIV Prevention in 125 participants. Completed in 30 August 2024.

Timeline

21 September 2017

Primary endpoint
16 August 2024

30 August 2024

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	125
Start date	21 September 2017
Primary completion	16 August 2024
Estimated completion	30 August 2024
Sites	1 location across United States

Drugs / interventions tested

Narrative Exposure Therapy (NET)
Motivational Interviewing w/Skills Training (MIST)

Conditions studied

HIV Prevention — all drugs for HIV Prevention →
PTSD and Substance Use Disorder — all drugs for PTSD and Substance Use Disorder →

Sponsor

University of Washington

Who can join

16 and older, any sex, with HIV Prevention or PTSD and Substance Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators will conduct a two-arm, comparative effectiveness randomized controlled trial of two culturally adapted, empirically based programs (EBP) - Narrative Exposure Therapy (NET) vs. Motivational Interviewing with Skills Training (MIST) in terms of lowering HIV sexual-risk behaviors (HSB) for American Indian / Alaska Native (AIAN) men and women. NET addresses Posttraumatic Stress Disorder (PTSD) as a pathway to preventing substance use disorders (SUD) and HSB whereas MIST addresses substance misuse as a way of preventing SUD and HSB.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A randomized comparison trial of culturally adapted HIV prevention approaches for Native Americans reducing trauma symptoms versus substance misuse: The Healing Seasons protocol.
Pearson CR, Kaysen D, Huh D, Bedard-Gillgan M, et al · · 2020 · cited 6× · PMID 32561467 · DOI 10.1016/j.cct.2020.106070
Adapting narrative exposure therapy with a tribal community: A community-based approach.
Bedard-Gilligan M, Kaysen D, Cordero RM, Huh D, et al · · 2022 · cited 4× · PMID 35621371 · DOI 10.1002/jclp.23395
A Community Engaged Approach in Adapting Motivational Interviewing and Skills Training for Native Americans With Experiences of Substance Misuse.
Walker D, Pearson C, Day A, Bedard-Gilligan M, et al · · 2023 · cited 1× · PMID 36869715 · DOI 10.1177/08901171231161467
A Randomized Comparison Trial Testing Two Culturally Adapted HIV Prevention Approaches for Native Americans Reducing Trauma Symptoms Versus Substance Misuse.
Pearson CR, Huh D, Bedard-Gilligan M, Walker D, et al · · 2025 · PMID 40524112 · DOI 10.1007/s10461-025-04777-w

Verify or expand the search:

Other trials of Narrative Exposure Therapy (NET)

Trials testing the same drug.

NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting

Other recruiting trials for HIV Prevention

Currently open trials in the same condition.

NCT07194902 — HIV Self-testing for Partners of HIV-uninfected Postpartum Women · NA · recruiting
NCT07218211 — Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP · Phase 4 · recruiting
NCT07349758 — Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers · Phase 1 · recruiting
NCT07433985 — California MEPS Hub · NA · recruiting
NCT07002866 — Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03112369 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03112369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing